Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAG Regimen vs 3+7 Chemotherapy Plus Gilteritinib in Newly Diagnosed FLT3-Mutated AML
NCT07407140Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of azacitidine, venetoclax in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
azacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07407140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407140.